Pfizer's results for Q3 2026 (quarter ended Sep 27, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-03. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $16,583 million (−0.4% vs a year earlier) |
| Diluted EPS (GAAP) | $0.56 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $0.87 |
| Full-year guidance | Raised |
Guidance
Pfizer raised 2026 revenue guidance to $62.0–64.0 billion and raised and narrowed adjusted EPS guidance to $2.95–3.05.
Why this label: Revenue guide raised to $62.0–$64.0B from $60.5–$62.5B; adjusted EPS raised and narrowed to $2.95–$3.05 from $2.80–$3.00.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| revenue | FY2026 | $62.0–64.0 billion | $60.5–62.5 billion |
| adjusted diluted EPS | FY2026 | $2.95–3.05 | $2.80–3.00 |
| adjusted R&D expenses | FY2026 | $10.8–11.8 billion | $10.5–11.5 billion |
From the release
Revenue: "Revenues · $ 16,583 · $ 16,654"
Earnings per share: "Third-Quarter 2026 Reported (4) Diluted EPS of $0.56, and Adjusted (3) Diluted EPS of $0.87"
revenue: "Raises full-year 2026 Revenue guidance (2) by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion from $60.5 to $62.5 billion previously."
adjusted diluted EPS: "Raises and narrows full-year 2026 Adjusted (3) diluted EPS guidance (2) to a range of $2.95 to $3.05 from $2.80 to $3.00 previously."
adjusted R&D expenses: "Adjusted (3) R&D Expenses · $10.8 to $11.8 billion · (previously $10.5 to $11.5 billion)"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 revenue guidance by $1.5 billion at midpoint to $62.0–64.0 billion
Source
Pfizer earnings release (SEC filing), accession 0000078003-26-000125, filed 2026-11-03.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.